GC
JUNO

Guggenheim Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Guggenheim Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-93,773
Closed -$4.29M – 2841
2017
Q4 		$4.29M Sell
93,773
-4,626
-5% -$231K 0.01% 1123
2017
Q3 		$4.41M Sell
98,399
-47,264
-32% -$1.61M 0.01% 1142
2017
Q2 		$4.35M Sell
145,663
-5,367
-4% -$132K 0.01% 1099
2017
Q1 		$3.35M Buy
151,030
+4,292
+3% +$92.1K 0.01% 1274
2016
Q4 		$2.77M Buy
146,738
+15,588
+12% +$381K 0.01% 1430
2016
Q3 		$3.94M Buy
131,150
+15,746
+14% +$490K 0.01% 1156
2016
Q2 		$4.44M Buy
115,404
+834
+0.7% +$34.6K 0.01% 1061
2016
Q1 		$4.36M Buy
114,570
+20,461
+22% +$713K 0.01% 1068
2015
Q4 		$4.14M Buy
94,109
+71,092
+309% +$3.53M 0.01% 1111
2015
Q3 		$937K Sell
23,017
-157,686
-87% -$6.92M ﹤0.01% 2134
2015
Q2 		$9.64M Buy
180,703
+105,403
+140% +$5.59M 0.02% 845
2015
Q1 		$4.57M Buy
+75,300
New +$3.65M 0.01% 1205

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Guggenheim Capital's JUNO Position: Q1 2018 in Review

Guggenheim Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 93,773 shares — an estimated $4.29M sold.

Guggenheim Capital first reported a position in JUNO in Q1 2015 and held it in 12 quarters. The position peaked at $9.64M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • Guggenheim Capital reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 93,773 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $4.29M.
  • Guggenheim Capital first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 12 quarters.
  • Guggenheim Capital's Juno Therapeutics, Inc. position peaked at $9.64M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.